Abstract 3431
Background
An increasing proportion of elderly patients (pts) are now being seen at cancer centres, with an increasing incidence of sarcoma. This has become a growing challenge for health care providers, because of the worse prognosis of these pts and our poor knowledge from trials, were they are underrepresented or excluded.
Methods
We performed a retrospective review of elderly pts with soft tissue and bone sarcomas treated between 2012 and 2017 at Regina Elena National Cancer Institute. Overall, 124 pts, median age of 77 (range 70-92), were evaluated for: surgery, radiotherapy (RT), medical treatment and related toxicities.
Results
The most common histological subtypes were: pleomorphic sarcoma (32%); liposarcoma (17%); leiomyosarcoma (13%); mixofibrosarcoma (9%); bone sarcoma (7%); and others (22%). A total of 107 pts had localized disease at diagnosis and 98 of them had surgical resection. 10 pts received adjuvant chemotherapy (CT) (8 Adriamicin (ADM), 1 Gemcitabine (Gem) and 1 Imatinib (IM)) and 35 pts adjuvant RT. 2 pts, unsuitable for surgery, were treated with RT, and 7 had best supportive care (BSC) (median age: 80, range: 73-85). Of the 17 metastatic pts, 13 were treated with palliative surgery. After surgery, 3 pts had RT and 3 had single agent CT (1 ADM, 1 Epirubicin (EPI) and 1 patient with GIST received IM followed by 2nd line Sunitinib). The remaining 3 pts had BSC due to age > 80 yr and PS 2. 10 non-metastatic pts had recurrent disease and were treated with 1st line CT (3 EPI, 1 Dacabarzine, 2 Gem, 1 Pazopanib, 1 ADM, 1 Docetaxel/Gem, 1 Bleomicine/Vinblastine). 6 received 2 lines of CT after progression (4 Trabectidin and 2 Gem). 13 of 21 pts treated with CT had no toxicities. The most common toxicities observed in 8 pts left were: haematological (37%); gastrointestinal (12%), and transaminitis (25%).
Conclusions
In our analysis, “fit” elderly pts were treated with the same medical treatments as non-elderly pts. Tolerability was fairly good, without discontinuation or hospitalization. Only 8% were treated with BSC, a relevant result considering the median age of our pts. Future studies designed for elderly pts and rare tumours, such as sarcomas, are needed to improve survival rates and quality of life of this poorly represented group of pts.
Clinical trial identification
Legal entity responsible for the study
Regina Elena Sarcoma Group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract